The prognostic value of immunocellular infiltration of non-invasive urothelial bladder cancer


Keywords: noninvasive urothelial bladder cancers, CD3 , CD4 , CD8 , CD 68 , CD20 cells.

Abstract

The aggressiveness of urothelial bladder cancers can be caused by reactions of stroma. Immunocompetent cells, which involved in antitumor response, are also able to stimulate tumor growth. Aim of the study: to study the features of immuncellular infiltration of non-invasive urothelial bladder cancers (NIUBC) to identify criteria for recurrence and progression prediction. Materials and methods: we formed three groups of studies, each of them contained 14 cases: NIUBC without recurrence — Group I, primary NIUBC with recurrence, but without progression — Group II, and primary NIUBC with recurrence and with progression — Group III. Immunohistochemistry was performed using primary monoclonal antibodies from DAKO to CD3, CD4, CD8, CD20 and CD68 cells. Statistical processing of research results was performed using the “Statistica 6.0” package. The relationship between parameters was studied by non-parametric Pearson χ-square test and Spearman test. A value of p<0.05 was considered statistically significant. Results: NIUBC I group was associated with weak stromal infiltration of immunocompetent cells: CD3 + lymphocytes (p<0.05), CD8 + T-killers (p<0.005) and CD68 + macrophages (p<0.005). In cancers of group III, immune cell infiltration was more observed than in cancers of groups I and II (p<0.001 and p<0.03) and was characterized by infiltration of CD3 + (p<0.01) and CD8 + cells (p<0.03). Thus, differentiation and recurrence of NIUBC progression depends on infiltration with immunocompetent cells, which can serve as a criterion for the disease prognosis. The prospect of further research – We are going to in-depth our research with studying importance of microenvironment of NIUBC, namely, immune cellular reactions, neoangiogenesis, connective tissue component at molecular-biological level. It will allow us to predict more accurate determination of NIUBC prognosis and choice of adequate treatment tactics.

Author Biography

E.V. Titov

Titov Evgeny Vyacheslavovich, Graduate student Kharkiv Medical Academy of Postgraduate Education https://orcid.org/0000-0002-1999-3052 , 066-01-02-477 , titovevgeniy@ukr.net

References

1. Lyulko, A. V. (2011). Rak mochevogo puzyirya v svete teorii immunnogo redaktirovaniya (literaturnyiy obzor) [Bladder cancer in the light of the theory of immune editing (literature review)]. UrologIya – Urology, 15 (1), 55–62.

. Ayari, C., La Rue, H., Hovington, H., Decobert, M., Harel, F., Bergeron, A., … Fradet, Y. Т. (2009). Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy. Eur. Urol., 55, 1386–95. doi: 10.1016/j.eururo.2009.01.040.

3. Desgrandchamps, F., LeMaoult, J., Goujon, A., Riviere, A., Rivero-Juarez, A., Djouadou, M., … Carosella, E. (2018). Prediction of non-muscle-invasive bladder cancer recurrence by measurement of checkpoint HLAG’s receptor ILT2 on peripheral CD8+ T cells. Oncotarget, 9 (69), 33160–33169. doi: 10.18632/oncotarget.26036.

4. Erdurak, K., Dundar, P. E., Ozyurt, B. C., Negri, E., La Vecchia, C., & Tay, Z. (2013). Smoking, occupation, history of selected diseasesand bladder cancer risk in Manisa, Turkey. European journal of cancer prevention, 23 (1), 58–61. doi: 10.1097/CEJ.0b013e3283631dde.

5. Józwicki, W., Brozyna, A. A., Siekiera, J., & Slominski, A. T. (2016). Changes in Immunogenicity during the Development of Urinary Bladder Cancer: A Preliminary Study. Int. J. Mol. Sci., 17, 285. doi:10.3390/ijms17030285.

6. Koti, M., Xu, А. S., Ren, K. Y. M., Visram, K., Ren, R., Berman, D. M., & Siemens, D. R. (2017). Tertiary Lymphoid Structures Associate with Tumour Stage in Urothelial Bladder Cancer. Bladder Cancer, 3 (4), 259–267. doi: 10.3233/BLC-170120.

7. Krpina, K., Babarovic, E., Dordevic, G., Fuckar, Z., & Jonjic, N. (2012). The association between the recurrence of solitary non-muscle invasive bladder cancer and tumor infiltrating lymphocytes. Croatian medical journal, 53 (6), 598–604. Epub 2013/01/01. PubMed PMID: 23275325.

8. Mantovani, A. (2011). Tumor-associated macrophages in cancer-related inflammation. Immunotherapy, 3(4 Suppl. 1), 21–22. Retrieved from https://www.futuremedicine.com/doi/pdfplus/10.2217/imt.11.32.

9. Pichler, R., Fritz, J., Zavadil, C., Schäfer, G., Culig, Z., & Brunner, A. (2016). Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guérin therapy in bladder cancer. Oncotarget, 7 (26), 39916–39930. doi: 10.18632/ oncotarget.9537.

10. Sjodahl, G., Lovgren, K., Lauss, M., Chebil, G., Patschan, O., Gudjonsson, S., ... Höglund, M. (2014). Infiltration of CD3 and CD68 cells in bladder cancer is subtype specific and affects the outcome of patients with muscle-invasive tumors. Urologic oncology, 32 (6), 791–7. doi: 10.1016/j.urolonc.2014.02.007.

11. Sui, X., Lei, L., Chen, L., Xie, T., & Li, T. (2017). Inflammatory microenvironment in the initiation and progression of bladder cancer. Oncotarget, 8 (54), 93279–93294. doi: 10.18632/ oncotarget. 21565.

12. Winerdal, M. E., Marits, P., Winerdal, M., Hasan, M., Rosenblatt, R., Tolf, A., ... Winqvist, O. (2011). FOXP3 and survival in urinary bladder cancer. BJU Int., 108 (10), 1672–1678. doi: 10.1111/j.1464-410X.2010. 10020.x.
Published
2019-03-01
How to Cite
Titov, E. (2019). The prognostic value of immunocellular infiltration of non-invasive urothelial bladder cancer. Reports of Vinnytsia National Medical University, 23(1), 129-133. https://doi.org/https://doi.org/10.31393/reports-vnmedical-2019-23(1)-22